These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8155384)

  • 1. Immunological response to intrathecal and systemic treatment with ganglioside antibody R-24 in patients with malignant melanoma.
    Dippold W; Bernhard H; Meyer zum Büschenfelde KH
    Eur J Cancer; 1994; 30A(2):137-44. PubMed ID: 8155384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.
    Vadhan-Raj S; Cordon-Cardo C; Carswell E; Mintzer D; Dantis L; Duteau C; Templeton MA; Oettgen HF; Old LJ; Houghton AN
    J Clin Oncol; 1988 Oct; 6(10):1636-48. PubMed ID: 3171629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats.
    Bergman I; Pohl CR; Venkataramanan R; Burckart GJ; Stabin M; Barmada MA; Griffin JA; Cheung NK
    J Immunother; 1999 Mar; 22(2):114-23. PubMed ID: 10093036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.
    Minasian LM; Yao TJ; Steffens TA; Scheinberg DA; Williams L; Riedel E; Houghton AN; Chapman PB
    Cancer; 1995 May; 75(9):2251-7. PubMed ID: 7536122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
    Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
    Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.
    Bajorin DF; Chapman PB; Wong GY; Cody BV; Cordon-Cardo C; Dantes L; Templeton MA; Scheinberg D; Oettgen HF; Houghton AN
    Melanoma Res; 1992 Dec; 2(5-6):355-62. PubMed ID: 1292783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.
    Houghton AN; Mintzer D; Cordon-Cardo C; Welt S; Fliegel B; Vadhan S; Carswell E; Melamed MR; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1242-6. PubMed ID: 3883355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
    Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody, 3F8.
    Bergman I; Barmada MA; Heller G; Griffin JA; Cheung NK
    Int J Cancer; 1999 Aug; 82(4):538-48. PubMed ID: 10404068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
    Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
    Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
    Cheung NK; Lazarus H; Miraldi FD; Abramowsky CR; Kallick S; Saarinen UM; Spitzer T; Strandjord SE; Coccia PF; Berger NA
    J Clin Oncol; 1987 Sep; 5(9):1430-40. PubMed ID: 3625258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.
    Nasi ML; Meyers M; Livingston PO; Houghton AN; Chapman PB
    Melanoma Res; 1997 Aug; 7 Suppl 2():S155-62. PubMed ID: 9578432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2.
    Irie RF; Morton DL
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8694-8. PubMed ID: 3464977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strong anti-tumor effect of monosialoganglioside specific monoclonal antibody 202: a clinical trial in a cancer patient with melanoma.
    Hamanaka S; Ota T; Nakayasu K; Kamei T; Tai T; Kawashima I; Otsuka F; Irie R; Asagami C
    J Dermatol; 1989 Dec; 16(6):480-6. PubMed ID: 2628455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
    Kawashima I; Tada N; Fujimori T; Tai T
    J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunorecognition of ganglioside epitopes: correlation between affinity and cytotoxicity of ganglioside antibodies.
    Dippold W; Bernhard H
    Eur J Cancer; 1992; 28A(10):1605-10. PubMed ID: 1382491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.
    Scott AM; Liu Z; Murone C; Johns TG; MacGregor D; Smyth FE; Lee FT; Cebon J; Davis ID; Hopkins W; Mountain AJ; Rigopoulos A; Hanai N; Old LJ
    Cancer Immun; 2005 Feb; 5():3. PubMed ID: 15723450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
    Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-alpha in patients with malignant melanoma.
    Caulfield MJ; Barna B; Murthy S; Tubbs R; Sergi J; Medendorp S; Bukowski RM
    J Biol Response Mod; 1990 Jun; 9(3):319-28. PubMed ID: 2380747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory tumor response to monoclonal antibody infusion.
    Dippold WG; Knuth KR; Meyer zum Büschenfelde KH
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):907-12. PubMed ID: 4043175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.